IntelGenx Technologies (OTCMKTS:IGXT) released its earnings results on Thursday. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01), reports. The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.90 million. IntelGenx Technologies had a negative return on equity of 209.70% and a negative net margin of 521.60%.
IGXT traded down $0.03 on Friday, hitting $0.41. 118,625 shares of the company were exchanged, compared to its average volume of 49,326. IntelGenx Technologies has a 12 month low of $0.39 and a 12 month high of $1.83. The company has a market cap of $40.87 million, a P/E ratio of -2.92 and a beta of 1.73. The company has a current ratio of 4.08, a quick ratio of 3.93 and a debt-to-equity ratio of 1.02. The company has a fifty day moving average price of $0.49.
A number of equities research analysts recently commented on the company. Zacks Investment Research cut IntelGenx Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, July 24th. Maxim Group reaffirmed a “buy” rating and set a $1.50 price objective on shares of IntelGenx Technologies in a research note on Friday.
IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease.
Read More: What is a price target?
Receive News & Ratings for IntelGenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.